LAWSUITS NEWS & LEGAL INFORMATION
Search Results for
Sort by date 2,440 pages found matching data breach- Opening Statements for Third Fosamax Trial Expected November 1st
Oct-23-10 New York, NY There have been about 1,000 lawsuits filed in the US alleging Fosamax osteonecrosis , which is a condition popularly known as dead jaw. However, there are other issues related to Fosamax. To that end the US Food and Drug Administration (FDA) issued a warning to consumers October 13th with regard to bisphosphonates (Fosamax among them). T... - FDA Employs Full Tool Box to Monitor Chantix
Oct-21-10 Washington, DC The horrific incidents involving attempted or successful Chantix suicide among other side effects prompted the US Food and Drug Administration (FDA) to require a post-approval risk evaluation and mitigation strategy (REMS), according to the October 8th issue of the Food and Drug Letter . Chantix—a smoking cessation drug—c... - Seroquel, Atypical Antipsychotics Linked to Increased Risk of Blood Clots
Oct-19-10 San Francisco, CA A new study suggests an increased risk of blood clots can be added to the list of potential Seroquel side effects . The list of reported Seroquel side effects already includes a risk of Seroquel birth defects and Seroquel tardive dyskinesia. Researchers in the United Kingdom, however, conducted a study that found patients taking atypic... - SSRI: Antidepressants Linked to Diabetes Risk
Oct-15-10 Baltimore, MD Could diabetes be added to the list of potential SSRI side effects ? It is too soon to tell, but two new studies have found a connection between antidepressants and diabetes. Selective serotonin reuptake inhibitors (SSRIs) already carry a warning about the risk of SSRI birth defects. Those birth defects include persistent pulmonary hyperte... - Canada Declares BPA a Toxin
Oct-15-10 Ottawa, ON The Canadian government has officially declared the plastic-making compound known as BPA – or bisphenol-A to be toxic, making it the first country in the world to do so. The decision represents the final regulatory step by the government, following a rigourous four-year study which resulted in Health Canada banning BPA from polycarb... - FDA Says Menaflex Collagen Scaffold Should not have Been Cleared
Oct-14-10 Washington, DC The U.S. Food and Drug Administration (FDA) today announced that an orthopedic device used in the knee should not have been cleared for marketing in the United States. The announcement follows a re-evaluation of the scientific evidence that was undertaken after a September 2009 agency report identified problems in the agency's review of... - All Marketed Sibutramine Drugs Voluntarily Withdrawn in Canada
Oct-13-10 Ottawa, ON Further to Health Canada's October 8, 2010, communication on the voluntary recall by Abbott Laboratories of Meridia (the brand name for the weight-loss drug sibutramine), Health Canada is updating healthcare practitioners and Canadians with respect to the two generic forms of sibutramine drugs authorized in Canada: Apo-sibutramine and Novo-s... - FDA Says Possible Increased Risk of Fracture with Bisphosphonates
Oct-13-10 Washington, DC The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates, a class of drugs used to prevent and treat osteoporosis. A labeling change and Medication Guide will reflect this risk. Bisphosphonates inhibit th... - Is Byetta's Manufacturer Pushing the Envelope?
Oct-9-10 STOCKHOLM Since the FDA's approval of Byetta (the first commercial product based on GLP-1) in May 2005, manufacturers Amylin Pharmaceuticals and Eli Lilly & Co. have been working hard to ensure that its diabetes drug reaps profits, which is likely a challenge for the giant pharmaceutical company, particularly since Byetta has been associated with... - Weight Loss Drug Meridia Pulled From US and Canadian Markets
Oct-8-10 Washington, DC The US Food and Drug Administration (FDA) is recommending against continued prescribing and use of Meridia (sibutramine) because this drug may pose unnecessary cardiovascular risks to patients. The FDA has requested that Abbott Laboratories—the manufacturer of Meridia—voluntarily withdraw this drug product from the Unite... - ATV Riders 50 Percent More Likely to Die Following an ATV Accident
Oct-6-10 Washington, DC Accidents on all terrain vehicles (ATVs), and the likelihood of dying after an ATV accident are more common than motorcycle accidents, trauma surgeons attending the annual meeting of the American College of Surgeons reported this week. In a study presented during the conference, reseachers cited some alarming numbers, including thos... - Norian to Pay $23 Million for Illegal Bone Cement Tests
Oct-5-10 Philadelphia, PA Norian Corp, accused of training surgeons to conduct unapproved clinical tests of its bone cement , "Norian SRS", has agreed to pay the maximum $23 million fine. Further, US prosecutors state that the company will admit criminality. In a report by the Associated Press (AP), Norian and its parent company Synthes Inc, are described a... - An Informed Consumer is Key to Avoiding Effexor Birth Defects
Oct-4-10 Montreal, PQ Earlier this summer, a Canadian study detailing some of the effects of Effexor and other antidepressants on pregnant women and their babies hit the pages of TIME Magazine . The study examined the relationship between selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and the older tricycl... - Baby Positioners Likely to be Banned
Oct-2-10 Washington, DC The FDA and Consumer Product Safety Commission (CPSC) have issued a warning that baby sleep positioners can carry the risk of suffocation and death. Health officials say the mats with barriers designed to prevent a baby from rolling over should not be used under any circumstances. The warning was prompted by reports of 12 deaths among... - Studies Question the Safety of Proton Pump Inhibitors
Oct-1-10 San Diego, CA In recent months, multiple studies questioning the safety of proton pump inhibitors (PPIs) have been published. The most recent study to examine the risk of proton pump inhibitor side effects suggests an association between the medication and increased mortality in older patients. Meanwhile, patients are being cautioned that PPIs should n... - Study: Fosamax, Other Drugs Double Risk of Esophageal Cancer
Sep-29-10 Oxford, UK A recent study has revealed that the use of Fosamax , along with other bone-building drugs, can double a patient's chance of developing esophageal cancer. Researchers from the University of Oxford in the UK examined medical records and found that the use of Fosamax and other oral bisphosphonates may increase the risk of developing esophage... - German Study Lauding Depakote Flawed, Says Editorial
Sep-28-10 BERLIN A German study on Depakote that was published in the summer may have been derailed by critics who feel the research raised more questions than it answered. Published in the 7/27/10 issue of Neurology , the study favored conventional antiepileptics such as Depakote over certain members of a newer crop of drugs. However, according to the 7/26/10... - FRS Energy: Magic Bullet or Sham?
Sep-25-10 Athens, GA It's called FRS energy and it's taken the weekend warrior market by storm. Lance Armstrong is its spokesperson. And FRS Co. has been snowballing from a growth standpoint, raising $23.1 million in new funding this past April and inking a distribution deal with giant PepsiCo in June. However, the jury is still out on the effectiveness value... - FRS Healthy Energy: Science or Scam?
Sep-22-10 Washington, DC It's like the Wild West when it comes to products such as FRS healthy energy drink . Dietary supplements still don't need to be proven safe and effective before hitting the shelves. And more often than not, these products are falsely advertised. If the FRS products actually lived up to the company's claims, why hasn't somebody won a Nobel... - British Medical Journal: Pull Avandia from Market
Sep-20-10 London, England The British Medical Journal recently said that the diabetes drug Avandia , made by GlaxoSmithKline, should be pulled from the market and, in fact, should never have been licensed at all. The journal found that the panel that had approved the medication prior to its entry into the European Union market in 2000 had concerns about pote...